Group 1 - The Hong Kong stock market is experiencing a new wave of share buybacks, with over 700 million shares repurchased in November and more than 300 million shares in the first half of December [1] - Leading technology companies are prominently driving this buyback trend, with Medtronic Technology (02158) being a notable example, having repurchased approximately 2.11 million shares for over 10.8 million HKD in December alone [1] - The company's buyback activity reflects its strong recognition of intrinsic value, supported by improved performance and business expansion, with adjusted EBITDA reaching approximately 54 million HKD, doubling year-on-year [1] Group 2 - Medtronic Technology's continuous buybacks signal value transmission and highlight the growth resilience of medical technology firms amid favorable performance and business development [2] - On December 12, the company's stock price rose over 3%, closing at 5.11 HKD [2]

Core Viewpoint - The Hong Kong stock market is experiencing a new wave of share buybacks, with significant participation from leading technology companies, particularly in the healthcare sector [1][2]. Group 1: Share Buyback Activity - In November, companies listed on the Hong Kong stock market repurchased over 700 million shares, with over 300 million shares repurchased in just the first few trading days of December [1]. - Medical technology company Yidu Tech (02158) has been a prominent player in this buyback trend, repurchasing 155,000 shares at HKD 5.1 per share on December 12, totaling approximately HKD 790,000 [1]. - Yidu Tech has conducted seven buybacks in December, accumulating around 2.11 million shares repurchased, with a total expenditure exceeding HKD 10.8 million [1]. Group 2: Company Performance and Developments - Yidu Tech's buyback activity reflects the company's strong recognition of its own value, supported by improved performance and business expansion [1]. - For the fiscal year 2026, Yidu Tech reported a significant improvement in profitability and operational efficiency, with adjusted EBITDA reaching approximately HKD 54 million, doubling compared to the same period last year [1]. - The company is making strides in AI healthcare innovation, participating in national AI application pilot projects in Beijing and winning bids for clinical research projects, as well as expanding its "Hui Min Bao" business in Hebei and Guangzhou [1].

Group 1 - The core point of the announcement is that Yidu Tech (02158.HK) repurchased 155,000 shares at a cost of HKD 790,000 on December 12, with the repurchase price ranging from HKD 5.09 to HKD 5.11 per share [1] - On December 11, Yidu Tech also repurchased 535,000 shares for a total cost of HKD 2.682 million [2]

Core Viewpoint - Yidu Tech (02158) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 155,000 shares at a total cost of HKD 790,700 [1] - The buyback price per share ranges from HKD 5.09 to HKD 5.11 [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan, intending to repurchase 155,000 shares at a total cost of HKD 790,700 [1] - The buyback price per share is set between HKD 5.09 and HKD 5.11 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年12月12日 (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發 ...

Group 1 - The company repurchased 535,000 shares at approximately HKD 5 per share, totaling over HKD 2.68 million, with a cumulative repurchase of nearly 2 million shares in December, exceeding HKD 10 million [1] - The company's total revenue for the fiscal year 2026 reached RMB 358 million, representing a year-on-year growth of 8.7%, with adjusted EBITDA of approximately RMB 54 million, doubling from the previous year [1] - The release of the first version of the commercial insurance innovative drug catalog in China is expected to provide new growth opportunities for the company, enhancing its ability to assist insurance companies in risk pricing and medical cost control [1] Group 2 - The company has provided comprehensive solutions for the "Hui Min Bao" projects in various provinces, serving over 40 million insured users [2] - The "Shenzhen Hui Min Bao," operated by the company, has included all 19 innovative drugs from the first version of the commercial insurance innovative drug catalog in its coverage for the 2025 fiscal year [2] - The company offers full-chain support for pharmaceutical companies, including clinical research services and market access strategies, enhancing the efficiency of drug development and commercialization [2]

Group 1 - Company repurchased 535,000 shares at approximately HKD 5 per share, totaling over HKD 2.68 million on December 11, with a cumulative repurchase of nearly 2 million shares in December, exceeding HKD 10 million [1] - The repurchase actions indicate that the company believes its stock is undervalued, and such actions should be supported by improvements in fundamentals [1] - The latest interim financial report for FY2026 shows total revenue of RMB 358 million, an 8.7% year-on-year increase, with adjusted EBITDA of approximately RMB 54 million, doubling from the previous year [1] Group 2 - The company has provided comprehensive solutions for "Hui Min Bao" projects in various regions, serving over 40 million insured users [2] - The "Shenzhen Hui Min Bao," operated by the company, has included all 19 innovative drugs from the first version of the commercial insurance innovative drug catalog in its coverage for the 2025 fiscal year [2] - The company offers full-chain support for pharmaceutical companies, enhancing R&D efficiency and providing critical services for market access and pricing strategies [2]

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan, intending to repurchase approximately 535,000 shares at a cost of about HKD 2.6816 million on December 11, 2025 [1]

Group 1 - Company Medu Technology (02158.HK) announced a share buyback on December 11, 2023, spending HKD 2.682 million to repurchase 535,000 shares [1] - The buyback price ranged from HKD 4.96 to HKD 5.08 per share [1]